Chemistry:Envonalkib
From HandWiki
Envonalkib is a pharmaceutical drug for cancer treatment.[1] It belongs to the class of anaplastic lymphoma kinase inhibitors (ALK inhibitors).[2]
In China, it is approved for the treatment of patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not received treatment with ALK inhibitors.[3]
References
- ↑ "Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial". Signal Transduction and Targeted Therapy 8 (1). August 2023. doi:10.1038/s41392-023-01538-w. PMID 37574511.
- ↑ "Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data". Frontiers in Oncology 15. 2025. doi:10.3389/fonc.2025.1566816. PMID 40416880.
- ↑ "Envonalkib Citrate Capsules Approved for Marketing by China NMPA". National Medical Products Administration. 2025-02-19. https://english.nmpa.gov.cn/2025-02/19/c_1073555.htm.
 |  |
